GSK adds Roy Jakobs to board as NED

GSK plc has appointed Roy Jakobs to its Board as an independent Non-Executive Director, effective 13 July 2026.

Rhea-AI Filing Summary

GSK plc has appointed Roy Jakobs to its Board as an independent Non-Executive Director, effective 13 July 2026. He is currently Chief Executive Officer of Royal Philips, a global health technology company with 2025 sales of 17.8 billion EUR and 65,000 employees.

GSK’s Board determined that Jakobs meets independence criteria under the UK Corporate Governance Code. He will receive the standard annual Non-Executive Director fee of £122,258 and is required to build a holding of GSK shares equal to two times this fee, in line with the shareholder-approved Non-Executive Director remuneration policy.

Key Figures

Royal Philips 2025 sales: 17.8 billion EUR Royal Philips employees: 65,000 employees GSK NED annual fee: £122,258 +2 more

5 metrics

Royal Philips 2025 sales 17.8 billion EUR Sales for Royal Philips in 2025

Royal Philips employees 65,000 employees Royal Philips global workforce

GSK NED annual fee £122,258 Standard annual fee for a GSK Non-Executive Director

Share ownership requirement 2x annual fee in GSK shares Non-Executive Director shareholding guideline

GSK CEO appointment date 13 July 2026 Effective date Roy Jakobs joins GSK Board

Key Terms

Non-Executive Director, UK Corporate Governance Code, Nominations & Corporate Governance Committee, Non-Executive Director Remuneration policy, +1 more

5 terms

Non-Executive Director financial

"Roy Jakobs will join the Board of the Company as a Non-Executive Director"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

UK Corporate Governance Code regulatory

"The Board has determined that Mr Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code"

Nominations & Corporate Governance Committee financial

"The appointment of Mr Jakobs was made by the Board on the recommendation of the Nominations & Corporate Governance Committee"

Non-Executive Director Remuneration policy financial

"in accordance with the Company's shareholder approved Non-Executive Director Remuneration policy"

Voluntary Code of Conduct for Executive Search Firms regulatory

"an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did GSK (GSK) announce in this Form 6-K?

GSK announced that Roy Jakobs will join its Board as an independent Non-Executive Director effective 13 July 2026. His appointment follows a skills-based search led by the Nominations & Corporate Governance Committee and supported by an external executive search firm.

Who is Roy Jakobs, the new GSK (GSK) Non-Executive Director?

Roy Jakobs is Chief Executive Officer of Royal Philips, a global health technology leader with 2025 sales of 17.8 billion EUR and 65,000 employees. He has held senior roles at Philips, Shell, and Elsevier and holds a Master’s in Business Administration.

How much will GSK (GSK) pay Roy Jakobs as a Non-Executive Director?

Roy Jakobs will receive GSK’s standard annual fee for a Non-Executive Director of £122,258. Under the company’s shareholder-approved Non-Executive Director remuneration policy, he must build a shareholding of GSK shares equal to two times this standard annual fee.

Is Roy Jakobs considered independent under GSK (GSK) governance standards?

GSK’s Board has determined that Roy Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code. His appointment was recommended by the Nominations & Corporate Governance Committee after assessing his skills, experience, and capacity to fulfil the role.

Does Roy Jakobs have a service contract with GSK (GSK)?

Roy Jakobs does not have a service contract with GSK. Instead, he has a letter of appointment governing his role as a Non-Executive Director, which can be viewed by contacting the Company Secretary at GSK’s registered office.

What share ownership requirement applies to GSK (GSK) Non-Executive Directors?

GSK requires Non-Executive Directors, including Roy Jakobs, to build a share ownership position in GSK shares equal to two times the standard annual Non-Executive Director fee. This requirement is set out in the company’s shareholder-approved Non-Executive Director Remuneration policy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 07:27 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 9 July 2026, London UK

Roy Jakobs to join GSK Board as Non-Executive Director

GSK plc (LSE/NYSE: GSK) has today announced that Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026. 

Mr Jakobs is currently Chief Executive Officer of Royal Philips, a global leader in health technology with sales of 17.8 billion EUR in 2025 and 65,000 employees worldwide, headquartered in Amsterdam, Netherlands.

Mr Jakobs has served as CEO of Royal Philips since 2022, and prior to that held international roles of increasing seniority after joining the company in 2010. Mr Jakobs has also held senior roles at other global companies including Shell and Elsevier, and holds a Master's in Business Administration (MBA).

Sir Jonathan Symonds, Chair of GSK said, "We are delighted to welcome Roy to the Board. His experience as CEO of a global health technology company, specialising in innovative adjacent technologies to biopharmaceuticals including patient monitoring, imaging, and intervention, will bring valuable perspective to Luke and the Board. Roy's values and approach to culture and purpose are highly aligned with our own, and he is well-placed to support GSK as we focus on accelerating growth and delivering better medicines for the patients who need them and greater value for shareholders."

Notes:

1.   The appointment of Mr Jakobs was made by the Board on the recommendation of the Nominations & Corporate Governance Committee. The Board agreed a target skills matrix for the role and was assisted and supported in candidate selection and evaluation by an external search firm, which is a signatory of the Voluntary Code of Conduct for Executive Search Firms. The Board satisfied itself that Mr Jakobs had the experience and time available to carry out the role.

2.   The Board has determined that Mr Jakobs is an independent Non-Executive Director in accordance with the UK Corporate Governance Code.

3.   Mr Jakobs will receive the standard annual fee for a Non-Executive Director of £122,258. He will be required to build towards a share ownership requirement of GSK shares in accordance with the Company's shareholder approved Non-Executive Director Remuneration policy - currently two times the standard annual fee. 

4.   Mr Jakobs does not have a service contract. He has a letter of appointment which may be viewed by contacting the Company Secretary at the Company's registered office.

5.   There are no further disclosures to be made in respect of Mr Jakobs' appointment under Listing Rule 6.4.8R.

6.   As of 13 July 2026, the Board of GSK will comprise:

Sir Jonathan Symonds CBE	Non-Executive Chair
Luke Miels	Chief Executive Officer
Julie Brown	Chief Financial Officer
Charles Bancroft	Senior Independent Non-Executive Director
Elizabeth McKee Anderson	Independent Non-Executive Director
Dr Hal Barron	Non-Executive Director
Dr Anne Beal	Independent Non-Executive Director
Wendy Becker CBE	Independent Non-Executive Director
Dr Hal Dietz	Independent Non-Executive Director
Roy Jakobs	Independent Non-Executive Director
Dr Jeannie Lee	Independent Non-Executive Director
Dr Gavin Screaton	Independent Non-Executive Director
Dr Vishal Sikka	Independent Non-Executive Director

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: July 09, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc